Relevant bibliographies by topics / Molecular pharming

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Molecular pharming'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Molecular pharming.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Molecular pharming"

1

Paul, Mathew, Craig van Dolleweerd, Pascal M. W. Drake, Rajko Reljic, Harry Thangaraj, Tommaso Barbi, Elena Stylianou, et al. "Molecular pharming." Human Vaccines 7, no. 3 (March 2011): 375–82. http://dx.doi.org/10.4161/hv.7.3.14456.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boscaiu, Monica, and Oscar Vicente. "Plant ‘molecular pharming’." Journal of Biotechnology 231 (August 2016): S6—S7. http://dx.doi.org/10.1016/j.jbiotec.2016.05.048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Humphreys, John M., and Clint Chapple. "Molecular ‘pharming’ with plant P450s." Trends in Plant Science 5, no. 7 (July 2000): 271–72. http://dx.doi.org/10.1016/s1360-1385(00)01680-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ramessar, Koreen, Teresa Capell, and Paul Christou. "Molecular pharming in cereal crops." Phytochemistry Reviews 7, no. 3 (February 23, 2008): 579–92. http://dx.doi.org/10.1007/s11101-008-9087-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Marsian, Johanna, and George P. Lomonossoff. "Molecular pharming — VLPs made in plants." Current Opinion in Biotechnology 37 (February 2016): 201–6. http://dx.doi.org/10.1016/j.copbio.2015.12.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Horn, Michael E. "Plant molecular pharming 2012 and beyond." Plant Cell Reports 31, no. 3 (February 4, 2012): 437–38. http://dx.doi.org/10.1007/s00299-012-1227-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Spalding, B. J. "Transgenic Pharming Advances." Nature Biotechnology 10, no. 5 (May 1992): 498–99. http://dx.doi.org/10.1038/nbt0592-498.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abdullah, M. A., Anisa ur Rahmah, A. J. Sinskey, and C. K. Rha. "Cell Engineering and Molecular Pharming for Biopharmaceuticals." Open Medicinal Chemistry Journal 2, no. 1 (May 14, 2008): 49–61. http://dx.doi.org/10.2174/1874104500802010049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ma, J. K. C. "Molecular pharming—innovation, product development and manufacture." New Biotechnology 25 (September 2009): S282. http://dx.doi.org/10.1016/j.nbt.2009.06.636.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lössl, Andreas G., and Jihong L. Clarke. "Conference Scene: Molecular pharming: manufacturing medicines in plants." Immunotherapy 5, no. 1 (January 2013): 9–12. http://dx.doi.org/10.2217/imt.12.146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Molecular pharming"

1

Pang, Ee Leen. "Molecular pharming of consensus dengue viral envelope glycoprotein domain III in planta and its immunogenicity profiles in BALB/c mice." Thesis, University of Nottingham, 2018. http://eprints.nottingham.ac.uk/52023/.

Full text
Abstract:
Dengue fever has emerged as one of the fastest growing health problems in recent years. Transmission of the mosquito-borne disease is widespread throughout the tropics, causing intriguing effects to the poorer populations with limited access to healthcare. At present, most vector control programmes have failed to contain the disease and no specific treatment is available yet. The existence of dengue virus as four distinct serotypes poses a significant threat as secondary infection is often manifested in a more severe form leading to hospitalisation and even death. Hence, this pushes the demand for a dengue vaccine as a long-term protective approach. Particularly for developing nations, cost is a major factor that needs to be meticulously addressed in order to provide a quick yet affordable medical relief. With that, this study aimed at producing a safe and cost-effective plant-based dengue subunit vaccine to protect against the febrile illness. A consensus sequence of the dengue envelope glycoprotein domain III (namely cEDIII) was selected as the antigenic determinant. cEDIII was expressed in two forms, i.e. as recombinant proteins with fusion to green fluorescent protein (sGFP) or cholera toxin B subunit (CTB), and as an epitope display on hepatitis B core antigen (HBcAg) virus-like particles (VLPs). All the constructs were cloned into pEAQ-HT vector and transient expression was achieved via agroinfiltration of Nicotiana benthamiana plants. Following the successful detection of heterologous proteins in N. benthamiana, purification procedures were carried out to harvest the recombinant proteins and chimeric HBcAg VLPs-displaying cEDIII, correspondingly. The recombinant fusion of cEDIII to CTB was shown to preserve the ability to fold into its active pentamer and bind with native gangliosides. Meanwhile, assembly of the chimeric HBcAg VLPs-displaying cEDIII was verified via transmission electron microscopy. These purified recombinant proteins and chimeric VLPs were then used for immunogenicity testing in BALB/c mice. Following vaccination with the recombinant protein, the results showed that successful production of anti-cEDIII specific response with neutralising potency against four dengue serotypes was obtained. T cell analyses suggested that the cEDIII induced a predominant T helper (Th) 1 response while the fusion with CTB could skew the response towards a mixed Th1/Th2. Immunisation with the chimeric VLPs-displaying cEDIII also achieved induction of cEDIII-specific responses, however, further evaluations are needed to warrant the successful use of these VLPs-based vaccines. Overall, the findings in this study have provided solid evidence that the development of a plant-based dengue vaccine is feasible. This is of crucial importance to battle against the upsurge of disease burden, and the production of a local vaccine could complement with Malaysian government’s efforts in combating dengue disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Vamvaka, Evangelia. "Rice endosperm as a production platform for third-generation HIV microbicides." Doctoral thesis, Universitat de Lleida, 2014. http://hdl.handle.net/10803/285629.

Full text
Abstract:
L’objectiu de la meva tesis doctoral és la producció en l’endosperma de l’arròs d’una tercera generació de microbicides contra el virus de la sida. Durant la meva recerca he utilitzat l’anticòs monoclonal 2G12 i dues proteïnes que neutralitzen el virus de la sida CV-N i GRFT, soles o en combinació, per a descobrir noves estratègies de producció. En la primera part he investigat si podia produir 2G12 a l’endosperma de l’arròs i quins eren els factors que influenciaven la seva producció. En la segona part de la meva tesis he introduït GRFT a l’endosperma de l’arròs i he analitzat si la proteïna expressada tenia activitat neutralitzant del virus de la SIDA. La expressió de GRFT en l’endosperma de l’arròs va ser comparable o inclús en algun cas més alta a GRFT expressada de forma transitòria en tabac. A la tercera part de la meva tesis he investigat si l’endosperma d’arròs seria una plataforma funcional per a la producció de CV-N i si aquesta proteïna tindria capacitat neutralitzant del virus de la sida. Finalment he utilitzat una combinació de microbicides 2G12, CV-N i GRFT per a introduir-les simultàniament a l’endosperma de l’arròs i identificar la millor combinació contra el virus de la sida, i si la co-expresió augmentava el seu efecte neutralitzant. Aquesta es la primera vegada que més d’una proteïna que neutralitzen el virus de la sida son produïdes de forma estable en l’endosperma d’un cereal, obrint un camí nou cap a la producció d’un còctel microbicida per a evitar la transmissió del virus de la sida.
El objetivo de mi tesis doctoral es la producción en el endospermo de arroz de una tercera generación de microbicidas contra el virus del SIDA. Durante mi trabajo de investigación utilicé el anticuerpo monoclonal 2G12 y dos proteínas que neutralizan el virus, CV-N y GRFT, solas o en combinación, para explorar diferentes estrategias de producción. En la primera parte de mi tesis investigué si podía producir 2G12 en el endospermo de arroz y cuáles eran los factores que afectaban a su producción. En la segunda parte de mi tesis, he introducido GRFT en el endospermo de arroz y he investigado si la proteína producida tenía actividad neutralizante del virus del SIDA. La expresión de GRFT en el endospermo del arroz fue comparable o incluso en algún caso más alta a GRFT producida de forma transitoria en tabaco. En la tercera parte de mi tesis he investigado si el endospermo de arroz sería una plataforma funcional para la producción de CV-N y si esta proteína sería capaz de neutralizar el virus del sida. La proteína Finalmente he utilizado una combinación de microbicidas 2G12, CV-N y GRFT para introducirlos simultáneamente en el endospermo de arroz e identificar la mejor combinación contra el virus del sida, y si la co-expresión potenciaba su efecto neutralizante. La combinación Esta es la primera vez que más de una proteína que neutraliza el virus del sida es producida de forma estable en el endospermo de un cereal, abriendo un nuevo camino hacia la producción de un cóctel microbicida para evitar la transmisión del virus del sida.
The focus of this thesis is the production of third-generation HIV microbicides in rice cells. I used one monoclonal antibody (2G12) and two anti-HIV proteins (CV-N and GRFT) alone or in combination, to explore different strategies to produce an efficient microbicide against HIV. The first part of my PhD thesis was to test whether rice endosperm can function as a platform for the production of 2G12 and to gain insight into the factors that affect the production and functional efficacy of neutralizing antibodies in plants. The human mAb2G12 was expressed successfully into rice endosperms as an aglycosylated form. In the second part of the thesis I introduced GRFT into rice endosperm and I tested whether the rice-derived GRFT protein retains its potent HIV-neutralizing activity. GRFT was successfully expressed in rice endosperm resulting in yields comparable or even higher to GRFT produced transiently in tobacco and other recombinant proteins. In the third part of my thesis I explored whether rice endosperm could function as a production platform to produce CV-N and I evaluated whether the rice-derived CV-N could neutralize efficiently the HIV virus. Finally I used a combinatorial approach introducing the 2G12, CV-N and GRFT into rice cells to identify the best combination against HIV, and whether their co-expression enhanced their effect. This is the first time that more than one protein against HIV is stable expressed into endosperm opening a new way for the production of a microbicide cocktail for the prevention of HIV transmission.
APA, Harvard, Vancouver, ISO, and other styles
3

Sabalza, Gallués Maite. "Maize seeds as a production and delivery platform for HIV microbicides." Doctoral thesis, Universitat de Lleida, 2013. http://hdl.handle.net/10803/127189.

Full text
Abstract:
La infecció pel virus de la immunodeficiència humana (VIH), és un dels problemes sanitaris i de desenvolupament més greus del món actual. Evitar la infecció és una de les estratègies que podria ajudar a reduir l’expansió del virus. Els microbicides són una nova classe de fàrmacs que podrien ajudar a realitzar-ho. Alguns dels reptes a superar que podrien frenar el desenvolupament de microbicides efectius son: que les molècules resultants siguin efectives, que la producció es pugui ampliar ràpidament i que els costos de producció puguin ser reduïts. Un dels sistemes de producció més prometedors son les plantes, al ser un sistema econòmic i segur. La producció de proteïnes recombinants farmacèutiques en plantes s’anomena “molecular pharming”. El principal objectiu d’aquesta tesis és la producció, individual o combinada, de molècules microbicides en llavors de blat de moro per tal de desenvolupar una nova estratègia de producció mes econòmica aplicable als països en vies de desenvolupament. La bioseguretat i els temes relacionats amb la legislació relativa a cultius millorats genèticament també són una part important d’aquesta tesi, ja que frenen el desenvolupament i la comercialització global d’aquest tipus de cultius.
El virus de la inmunodeficiencia humana (VIH) es en la actualidad uno de los problemas de salud pública más graves en el mundo. La aplicación de medidas preventivas para evitar la infección por VIH es la principal vía para reducir la expansión del virus. Los microbicidas son una nueva clase de productos antivirales de bajo coste que podrían ayudar a conseguirlo. Algunos de los obstáculos que pueden frenar el desarrollo de microbicidas son la viabilidad, el aumento de área de cultivo y los altos costes de producción. Se están evaluando muchas plataformas para la producción de microbicidas. Una de las más prometedoras son las plantas, ya que constituyen un sistema económico y seguro. A la producción de proteínas recombinantes farmacéuticas en plantas se le denomina “molecular pharming”. El principal objetivo de esta tesis es el estudio de la producción de moléculas microbicidas tanto a nivel individual (una sola molécula) como combinada (simultaneamente varias moléculas) en semillas de maíz con el fin de desarrollar una nueva estrategia mas económica capaz de evitar la infección por VIH en países en vías de desarrollo. La bioseguridad y los temas relacionados con la legislación relativa a cultivos mejorados genéticamente también son una parte importante de esta tesis, ya que limitan el desarrollo y la comercialización global de este tipo de cultivos.
HIV remains one of the world’s most serious health and development challenges. Preventing HIV infection is one of the strategies that could slow down the spread of the virus. Microbicides are a new class of products that could address this need. However, the feasibility of manufacturing, scalability, and cost are some of the challenges that can undermine the development of cost effective microbicides. One of the most promising production systems is plants because of cost benefits and biological safety. Production of medically important recombinant proteins in plants is known as molecular pharming. The focus of this thesis is the production of microbicide components individually or in combination in maize seeds in order to develop a novel and inexpensive strategy for the prevention of HIV infections in the developing world. I also discuss non-technical barriers to the adoption of GE crops in the European Union and their serious consequences.
APA, Harvard, Vancouver, ISO, and other styles
4

Gomes, Carolina Nogueira Carvalho. "Production and analysis of pharmaceutically relevant peptides in Lactuca sativa and Medicago truncatula." Master's thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/21655.

Full text
Abstract:
Mestrado em Biotecnologia Alimentar
O molecular pharming permite a produção de proteinas terapêuticas recombinantes a larga escala, de forma segura e a baixo custo. No presente trabalho, é proposta a produção heteróloga de quatro péptidos inibidores da ACE em dois emergentes sistemas de expressão vegetal, Lactuca sativa (alface) e Medicago truncatula (luz cortada). A utilização da alface, uma planta comestível, pode proporcionar um meio para a administração oral de péptidos anti-hipertensivos, criando um novo alimento funcional. Por outro lado, a utilização de M. truncatula, uma leguminosa modelo, garante não só a facilidade de transformação mas também a extrapolação processual para outras leguminosas. No contexto actual de demanda por terapias alternativas para a hipertensão e de processos mais eficientes de produção de péptidos inibidores da ACE, este trabalho assume particular importância.
Molecular pharming is a cost-effective, scalable and safe system to produce high-quality and biologically active recombinant therapeutic proteins. In the present work the heterologous production of four ACE inhibitory peptides in two emerging plant expression hosts, Lactuca sativa (lettuce) and Medicago truncatula is proposed. The use of lettuce, an edible plant, can provide a means for oral delivery of antihypertensive peptides, thus creating a novel functional food. On another hand, the use of M. truncatula, a model legume, ensures not only the simple transformation process but also the procedural extrapolation to other legume species. In the current scenario of global demand for alternative hypertension therapies and easier ACE inhibitory peptide manufacturing processes, this work assumes particular importance.
APA, Harvard, Vancouver, ISO, and other styles
5

Oliveira, Ana Lúcia da Silva. "Molecular pharming in Lactuca sativa L. (Lettuce) : development of protocols." Master's thesis, 2009. http://hdl.handle.net/1822/10869.

Full text
Abstract:
Dissertação de mestrado em Biotecnologia e Bio-empreendedorismo de Plantas Aromáticas e Medicinais
Agrobacterium tumefaciens- mediated genetic transformation is an indispensable tool used for the production of genetically modified plants. In our laboratory, we have established a transformation system for lettuce (Lactuca sativa L.) cultivars Batávia Blonde, Butterhead and Queen of May, using Agrobacterium strain EHA 105. Five-day-old mature cotyledon explants was used for transformation study. The selection of transformed shoots was carried out in MS medium fortified with BA (0.1 mg L), NAA (0.1 mg/L) and under the selection of Kanamycin sulphate (50 to BB and 100mg/L to BH and QM) and Ticarcillin (250 mg/L). The transient GUS expression assay was carried out in order to find transformed shoots and to asses the influence of the genotype in the infection process. No differences were found between varieties in the T-DNA transfer rate (100%), but it was observed different behaviours during the regeneration process. Thus, it was shown that the genotype influences the response of different varieties during regeneration but not influences the predisposition to infection by A. tumefaciens. The molecular confirmation by PCR and Southern blot of transformed shoots revealed the foreign gene integration into lettuce genome. The reporter gene show a segregation pattern of Mendel in lettuce, since the generations T1 and T2 had a segregation ration of 3:1. It was proven that the gene gusA has no influence in the phenolic profile of the plants, since no differences were found in the type of compounds produced between transgenic plants and non-transgenic. Having established the protocol for infection of L. sativa L., in an attempt to demonstrate the applicability of this method, it was constructed an expression vector for an animal protein, leukaemia inhibitor factor (LIF), wich has not yet been expressed in plants. The construction of this vector will allow the expression of LIF in plants like lettuce and future studies on LIF yield production and purification in systems like plants. In this way will be possible to compare the different methods to produce LIF and select the ideal.
Transformação mediada por Agrobacterium tumefaciens- é uma ferramenta indispensável na produção de plantas geneticamente modificadas. O presente estudo foi efectuado de forma a estabelecer um sistema de transformação eficiente para diferentes variedades de alface (Batávia Blonde, Butterhead e Queen of May), usando a estirpe de Agrobacterium EHA105. Cotilédones com cinco dias de idade foram usados no estudo de transformação. A selecção dos rebentos caulinares desenvolvidos foi efectuado em meio basal MS suplementado com BA e NAA a 0.1 mg/L e sobre a selecção de canamicina a 50mg/L para Batávia Blonde e 100mg/L para Butterhead e Queen of May e ticarcilina a 250mg/L. A expressão do gene gusA foi realizada para detectar rebentos transformados e verificar a influência do genótipo no processo de infecção. Não foram detectadas diferenças entre as variedades no que diz respeito à percentagem de transferência de T-DNA (100%). Pelo contrário foram detectadas diferenças entre as variedades no processo de regeneração. Isto demonstra que o genótipo exerce influência na resposta das diferentes variedades no processo regenerativo mas não tem influência na prédisposição das plantas para a infecção por Agrobacterium. A confirmação da integração do gene no genoma foi feita por análise de PCR e Southern blot. O gene repórter demonstrou que na alface transformada houve segregação do gene segundo Mendel, já que as gerações T1 e T2 apresentaram segregação 3:1. Foi provado que o gene gusA não exerceu influência no perfil fenólico das plantas já que não foram observadas diferenças significativas entre planas transgénicas e não transgénicas. Uma vez estabelecido um protocolo de infecção de L. sativa L., de forma a demonstrar a aplicabilidade do método, foi construído um vector de expressão para a proteína animal Leukaemia inhibitory factor (LIF), proteína que ainda não foi expressa em plantas. A construção deste vector permitirá a expressão de LIF em plantas como a alface e permitirá a realização de futuros estudos relativamente ao rendimento da produção da proteína e purificação. Desta forma será possível comparar os diferentes métodos para a produção de LIF e seleccionar o ideal.
APA, Harvard, Vancouver, ISO, and other styles
6

Oliveira, Filipe Silva Nunes de. "Heterologous production of oligopeptides with antihypertensive effects in Lactuca sativa and Medicago truncatula." Master's thesis, 2018. http://hdl.handle.net/10362/47275.

Full text
Abstract:
“In the current scenario of a worldwide problematic situation related to cardiovascular diseases associated with hypertension, the necessity for alternative therapies has become a great challenge. The need for therapies with little side effects and with the same efficacy, but less expensive, has given the opportunity to the new biotechnological paradigm brought by molecular pharming to win its market share from the established pharmaceutical industry. Molecular pharming is a costeffective, scalable and safe system to produce high-quality and biologically active recombinant therapeutic proteins. Medicago truncatula and Lactuca sativa (lettuce) are two emerging plant hosts for molecular pharming. M. truncatula is a model legume plant amenable for transformation and in vitro manipulation, along with the procedural extrapolation to other legume species. L. sativa is a worldwide raw edible plant which allows the oral delivery of recombinant therapeutic products. In the present work, the heterologous production of four ACEI peptides - that have proven antihypertensive effect – in Medicago and lettuce hosts was analyzed. The ACEI peptides production was verified at leaf level in the two plant production hosts. An in vitro plant stock was kept to allow the progression of the work, and a seed bank was established to allow further studies in the progeny. The presence of the ACEI coding sequences transcripts in Medicago RNA samples confirmed the stable transformation of this host. In the lettuce host, an in vitro seed selection scheme based on kanamycin was established to screen ACEI transformants which were further analyzed at genomic DNA level confirming the stable plant transformation with ACEI coding sequences. At protein production level, protocols for the peptide extraction, along with ELISA, SDS-PAGE, western immunoblotting, and HPLC were established for further detection and quantification of ACEI peptide production.”
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Molecular pharming"

1

Kermode, Allison R., and Liwen Jiang, eds. Molecular Pharming. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kermode, Allison R., and Liwen Jiang. Molecular Pharming: Applications, Challenges and Emerging Areas. Wiley & Sons, Incorporated, John, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kermode, Allison R., and Liwen Jiang. Molecular Pharming: Applications, Challenges and Emerging Areas. Wiley & Sons, Incorporated, John, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kermode, Allison R., and Liwen Jiang. Molecular Pharming: Applications, Challenges and Emerging Areas. Wiley & Sons, Incorporated, John, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Molecular pharming"

1

Chen, Qiang, Matthew Dent, and Hugh Mason. "Molecular Pharming." In Molecular Pharming, 231–73. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Spiegel, Holger, Eva Stöger, Richard M. Twyman, and Johannes F. Buyel. "Current Status and Perspectives of the Molecular Farming Landscape." In Molecular Pharming, 1–23. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yang, Daichang, Jiquan Ou, Jingni Shi, Zhibin Guo, Bo Shi, and Naghmeh Abiri. "Transgenic Rice for the Production of Recombinant Pharmaceutical Proteins." In Molecular Pharming, 275–307. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hood, Elizabeth E., and Carole L. Cramer. "Enzymes for Industrial and Pharmaceutical Applications - From Individual to Population Level Impact." In Molecular Pharming, 309–25. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hundleby, Penny A. C., Markus Sack, and Richard M. Twyman. "Biosafety, Risk Assessment, and Regulation of Molecular Farming." In Molecular Pharming, 327–51. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tissier, Alain. "Harnessing Plant Trichome Biochemistry for the Production of Useful Compounds." In Molecular Pharming, 353–82. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fidan, Ozkan, and Jixun Zhan. "Reconstitution of Medicinally Important Plant Natural Products in Microorganisms." In Molecular Pharming, 383–415. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Feng, Li, and Jingwu Kang. "Screening of Epidermal Growth Factor Receptor Inhibitors in Natural Products Derived From Extracts of Traditional Chinese Medicines." In Molecular Pharming, 417–33. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Littleton, John, Dustin Brown, Deane Falcone, Gregory Gerhardt, Samir Gunjan, Dennis T. Rogers, and Jatinder Sambi. "Target-Directed Evolution of Mutant Transgenic Plant Cells as a Novel Source of Drugs." In Molecular Pharming, 435–56. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Basak, Indranil, and Simon G. Møller. "Plant Thermotolerance Proteins, Misfolded Proteins, and Neurodegenerative Diseases." In Molecular Pharming, 457–74. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118801512.ch18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Molecular pharming' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography